Literature DB >> 24051213

Regulation of the Hippo pathway and implications for anticancer drug development.

Hyun Woo Park1, Kun-Liang Guan.   

Abstract

Research in the past decade has revealed key components of the Hippo tumor suppressor pathway and its critical role in organ size regulation and tumorigenesis. Recent progress has identified a wide range of upstream factors that control the Hippo pathway, which include cell-cell contact, various diffusible signals, and cognate receptors. Dysregulation of the Hippo pathway, caused by gene mutation or aberrant expression, promotes cell proliferation and tumorigenesis. Here, we discuss the current state of Hippo pathway research, primarily focusing on upstream regulators and protein-protein interactions as potential therapeutic targets. Consideration of pharmacological intervention of the Hippo pathway may provide novel avenues for future therapeutic treatment of human diseases, particularly in cancer.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GPCR; Hippo pathway; YAP; cancer; phosphorylation

Mesh:

Substances:

Year:  2013        PMID: 24051213      PMCID: PMC3929107          DOI: 10.1016/j.tips.2013.08.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  108 in total

1.  The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells.

Authors:  Michelangelo Cordenonsi; Francesca Zanconato; Luca Azzolin; Mattia Forcato; Antonio Rosato; Chiara Frasson; Masafumi Inui; Marco Montagner; Anna R Parenti; Alessandro Poletti; Maria Grazia Daidone; Sirio Dupont; Giuseppe Basso; Silvio Bicciato; Stefano Piccolo
Journal:  Cell       Date:  2011-11-11       Impact factor: 41.582

Review 2.  Autotaxin and LPA receptor signaling in cancer.

Authors:  Anna J S Houben; Wouter H Moolenaar
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Hippo pathway regulation by cell morphology and stress fibers.

Authors:  Ken-Ichi Wada; Kazuyoshi Itoga; Teruo Okano; Shigenobu Yonemura; Hiroshi Sasaki
Journal:  Development       Date:  2011-08-10       Impact factor: 6.868

Review 4.  The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal.

Authors:  Bin Zhao; Karen Tumaneng; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2011-08-01       Impact factor: 28.824

5.  E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components.

Authors:  Nam-Gyun Kim; Eunjin Koh; Xiao Chen; Barry M Gumbiner
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

Review 6.  14-3-3 proteins as potential therapeutic targets.

Authors:  Jing Zhao; Cheryl L Meyerkord; Yuhong Du; Fadlo R Khuri; Haian Fu
Journal:  Semin Cell Dev Biol       Date:  2011-10-01       Impact factor: 7.727

7.  A Smad action turnover switch operated by WW domain readers of a phosphoserine code.

Authors:  Eric Aragón; Nina Goerner; Alexia-Ileana Zaromytidou; Qiaoran Xi; Albert Escobedo; Joan Massagué; Maria J Macias
Journal:  Genes Dev       Date:  2011-06-15       Impact factor: 11.361

8.  The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene.

Authors:  X Zhang; J George; S Deb; J L Degoutin; E A Takano; S B Fox; D D L Bowtell; K F Harvey
Journal:  Oncogene       Date:  2011-02-14       Impact factor: 9.867

9.  A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription.

Authors:  Yijun Bao; Kentaro Nakagawa; Zeyu Yang; Mitsunobu Ikeda; Kanchanamala Withanage; Mari Ishigami-Yuasa; Yukiko Okuno; Shoji Hata; Hiroshi Nishina; Yutaka Hata
Journal:  J Biochem       Date:  2011-05-17       Impact factor: 3.387

10.  PP1A-mediated dephosphorylation positively regulates YAP2 activity.

Authors:  Pei Wang; Yujie Bai; Bangrong Song; Yadong Wang; Dong Liu; Yongqiang Lai; Xiaolin Bi; Zengqiang Yuan
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

View more
  63 in total

1.  The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.

Authors:  Lin Zhang; Shuping Yang; Xingcheng Chen; Seth Stauffer; Fang Yu; Subodh M Lele; Kai Fu; Kaustubh Datta; Nicholas Palermo; Yuanhong Chen; Jixin Dong
Journal:  Mol Cell Biol       Date:  2015-02-02       Impact factor: 4.272

Review 2.  YAP and TAZ: a nexus for Hippo signaling and beyond.

Authors:  Carsten Gram Hansen; Toshiro Moroishi; Kun-Liang Guan
Journal:  Trends Cell Biol       Date:  2015-06-02       Impact factor: 20.808

3.  Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration.

Authors:  W Mi; Q Lin; C Childress; M Sudol; J Robishaw; C H Berlot; M Shabahang; W Yang
Journal:  Oncogene       Date:  2014-08-11       Impact factor: 9.867

4.  Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.

Authors:  Kristianne M Oristian; Lisa E S Crose; Nina Kuprasertkul; Rex C Bentley; Yi-Tzu Lin; Nerissa Williams; David G Kirsch; Corinne M Linardic
Journal:  Cancer Res       Date:  2018-08-09       Impact factor: 12.701

5.  YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?

Authors:  Fiorina Kyritsi; Douglas K Price; William D Figg
Journal:  Cancer Biol Ther       Date:  2016-05-05       Impact factor: 4.742

6.  Targeting YAP Degradation by a Novel 1,2,4-Oxadiazole Derivative via Restoration of the Function of the Hippo Pathway.

Authors:  Eman M E Dokla; Chun-Sheng Fang; Po-Chen Chu; Chih-Shiang Chang; Khaled A M Abouzid; Ching S Chen
Journal:  ACS Med Chem Lett       Date:  2020-03-05       Impact factor: 4.345

7.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

8.  Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.

Authors:  Nicholas Theodosakis; Casey G Langdon; Goran Micevic; Irina Krykbaeva; Robert E Means; David F Stern; Marcus W Bosenberg
Journal:  Pigment Cell Melanoma Res       Date:  2018-10-22       Impact factor: 4.693

9.  The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.

Authors:  Carsten Gram Hansen; Yuen Lam Dora Ng; Wai-Ling Macrina Lam; Steven W Plouffe; Kun-Liang Guan
Journal:  Cell Res       Date:  2015-11-27       Impact factor: 25.617

10.  Fat4 suppression induces Yap translocation accounting for the promoted proliferation and migration of gastric cancer cells.

Authors:  Liangang Ma; Jianxin Cui; Hongqing Xi; Shibo Bian; Bo Wei; Lin Chen
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.